ARTL (Artelo Biosciences, Inc. Common Stock) Stock Analysis - Hedge Fund Holdings
Artelo Biosciences, Inc. Common Stock (ARTL) is a publicly traded Healthcare sector company. As of May 21, 2026, ARTL trades at $1.43 with a market cap of $3.19M and a P/E ratio of 0.00. ARTL moved +3.68% today. Year to date, ARTL is -63.59%; over the trailing twelve months it is -91.84%. Its 52-week range spans $1.25 to $85.80. Rallies surfaces ARTL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Who owns ARTL stock?
Rallies tracks hedge fund and 13F ownership for ARTL, including fund holders, share counts, and position changes when data is available.
Gorgas Gregory D. bought 1.20K (~$4.80K) on Aug 12, 2022.
Gorgas Gregory D. bought 1.20K (~$4.84K) on Aug 11, 2022.
ARTL Analyst Consensus
ARTL analyst coverage data. Average price target: $0.00.
Common questions about ARTL
Who owns ARTL stock?
Rallies tracks hedge fund and 13F ownership for ARTL, including fund holders, share counts, and position changes when data is available.
Does Rallies show 13F holders for ARTL?
Yes. Rallies tracks hedge fund and 13F ownership data for ARTL, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ARTL research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ARTL. It does not provide personalized investment advice.